A panelist discusses how patient comorbidities and declining performance status drive individualized treatment planning in relapsed ES-SCLC.
A 59-Year-Old Woman with Relapsed Extensive-Stage Small Cell Lung Cancer
A panelist discusses how early relapse and prognostic indicators shape second-line therapy selection and emerging treatment roles.
A panelist discusses how tarlatamab’s strong efficacy data suggest a practice-changing advance for relapsed ES-SCLC.
A panelist discusses how proactive management of CRS and ICANS supports safe community use of DLL3-targeted therapy.
A panelist discusses how lurbinectedin and tarlatamab both remain essential options within evolving treatment strategies.
A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
2
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
3
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
4
MB-105 Gains FDA RMAT Designation in R/R T-Cell Lymphoma
5
